Investor Presentation for the quarter ended June 30, 2026

Ref: MHL/Sec&Legal/2026-27/33 August 04, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation for the quarter ended June 30, 2026. A copy of the said presentation is also being uploaded on the Company’s website at www.metropolisindia.com. You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head - Legal & Secretarial Encl.: a/a Q1 FY27 Investor Presentation Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been Certain matters discussed in this Presentation may contain statements regarding the prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely Company’s market opportunity and business prospects that are individually and for information purposes and do not constitute any offer, recommendation or invitation to collectively forward-looking statements. Such forward-looking statements are not purchase or subscribe for any securities, and shall not form the basis or be relied on in guarantees of future performance and are subject to known and unknown risks, connection with any contract or binding commitment whatsoever. No offering of securities uncertainties and assumptions that are difficult to predict. These risks and uncertainties of the Company will be made except by means of a statutory offering document containing include, but are not limited to, the performance of the Indian economy and of the detailed information about the Company. economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company’s ability to successfully implement its This Presentation has been prepared by the Company based on information and data strategy, the Company’s future levels of growth and expansion, technological which the Company considers reliable, but the Company makes no representation or implementation, changes and advancements, changes in revenue, income or cash flows, warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, the Company’s market preferences and its exposure to market risks, as well as other accuracy, completeness, fairness and reasonableness of the contents of this risks. The Company’s actual results, levels of activity, performance or achievements could Presentation. This Presentation may not be all inclusive and may not contain all of the differ materially and adversely from results expressed in or implied by this Presentation. information that you may consider material. Any liability in respect of the contents of, or The Company assumes no obligation to update any forward-looking information contained any omission from, this Presentation is expressly excluded. in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Metropolis - diagnostics that’s trusted by doctors and patients alike 209 35 2 OUR VISION Clinical Labs ISO:15189 Accredited CAP Accredited Labs Labs 31 India / 4 Kenya India OUR BRAND PROMISE 45 4,500 5,000 + + + Years of credible Tests & Profiles Service Network 12% CAGR revenue growth over experience the last 7 years Q 1 F Y 2 7 Key Financial Highlights REVENUE EBITDA PAT INR 450 Cr INR 113 Cr INR 57 Cr 17% YoY 27% YoY 26% YoY NETWORK EBITDA MARGIN PAT MARGIN 5,003 25.2% 12.6% 8% YoY 210 bps 90 bps ● Mid-teen revenue growth delivered despite no ● Q1FY27 EBITDA grew by 210 bps driven by ● Sustained demand momentum and increasing price hikes , demonstrating strong underlying operating leverage, automation, and continued throughput from the expanded Lab & Center demand and volume -led growth process efficiencies. network enabled the company to outperform its growth guidance. Q 1 F Y 2 7 Key Performance Indicators B2C REVENUE B2B REVENUE TRUHEALTH INR 257 Cr INR 193 Cr INR 81 Cr 18% YoY 15% YoY 22% YoY PATIENT VOLUME TEST VOLUME SPECIALTY 3.7 Mn 7.8 Mn INR 178 Cr 10% YoY 11% YoY 17% YoY ● Double -digit patient and test volume growth , ● 17% growth in specialty testing revenues, led by ● B2C powered by micro -marketing and brand pull ; aided by deeper market penetration, the shift successful upselling and Pan -India integration of B2B strengthened by service excellence and a from unorganised to trusted chain labs and the Core Diagnostics test menu. wider clinician network. Tier -3+ expansion. Q 1 F Y 2 7 Consistently delivering patient & test volume growth Patient Volume Test Volume Revenue Per Patient Revenue Per Test Q1FY27 Segment Q1FY27 Segment Contribution Revenue Growth (in Mn) (in Mn) (INR) (INR) 3.69 7.83 1,219 575 1,151 546 3.35 7.07 TruHealth 22% Specialty 17% Semi -Special 15% Specialty 40% Semi -Spl 25% Routine 13% TruHealth 18% Routine 17% Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 +10% +11% +6% +5% Q 1 F Y 2 7 · C H A N N E L M I X B2C revenue up 18% YoY & B2B revenue up 15% YoY B2C · 57% B2B · 43% B2C B2B +18% YoY +15% YoY Own, franchisee & rural centres B2B labs, hospitals, government, corporate & clinical trials TruHealth Growth Specialty Growth TruHealth Growth Specialty Growth +22% +21% +23% +15% Micro -marketing strategies and strong • Improving business quality, service brand pull enabling volume -led growth excellence and ease of doing Tier -3 and beyond expansion widening business B2C reach and patient acquisition • Driving stronger specialty -led growth Digital, app and AI -led initiatives • Widening clinician and institutional improving TruHealth conversion network Premiumisation through Vitals, Consult and ECG offerings MetLink – Flagship Franchisee Partner B2B Partner training and Engagement Engagement Programme Q 1 F Y 2 7 R E V E N U E G R O W T H TruHealth & Speciality TruHealth Speciality Strong revenue momentum, premium mix & digital acceleration GROWTH CONTRIBUTION GROWTH CONTRIBUTION 22% 18% 17% 40% ● Radiology -integrated wellness packages ● grew 40%+ through range optimisation and focused upselling. ● Premium TruHealth packages grew ● 50%+, led by doctor consult, vitals and ECG -led extensions. ● Launched AI -enabled personalised ● nutrition and TruHealth Mind & Body for Series of Genomics Symposiums cognitive wellness. Wellness Zone at Key Centres for across the country for Specialist Consultative TruHealth ● Introduced dedicated Wellness Zones at ● Connect marquee centres for consultative wellness delivery. Q 1 F Y 2 7 · R E A C H Diversified revenue contribution across geographies By Region By City Tier West 50% Tier I 67% South 27% Tier II 7% North 18% Tier III 26% East 6% Region Growth Tier Growth West 14% Tier I 11% South 14% Tier II 14% North 19% Tier III 25% North India contribution, up from 17% East 11% Revenue contribution of domestic revenue only. Map not to scale; for illustrative purposes only. I N F R A S T R U C T U R E Building a scalable, efficient network Laboratory Network Service Network 5,026 5,003 4,536 210 212 209 4,150 3,675 3,134 125 2,555 FY21 FY22 FY23 FY24 FY25 FY26 Q1FY27 FY21 FY22 FY23 FY24 FY25 FY26 Q1FY27 Over the last 5 years 87 labs added to the network. In Q1FY27, Over the last 5 years 2,471 service points added consolidated 7 labs with acquired entities ~750 295 service points added in Q1FY27 with 24:1 Centre: Lab Ratio improved over 21:1 LY. rationalisation of 318 non -productive centres Q 1 F Y 2 7 Consolidated Profit & Loss Statement Profit & Loss Statement Q1FY27 Q1FY26 Y -o-Y Revenue from Operations 450.2 386.1 16.6% Total Cost 337.0 296.9 EBITDA 113.2 89.1 27.1% EBITDA Margin (%) 25.2% 23.1% 210 bps Depreciation 32.4 30.8 Other Income 5.1 7.5 EBIT 86.0 [Showing first 8,000 characters — download PDF for full document]